Abstract
Several controlled trials have shown that administration of interferon-α for some months with a dosage about 3 million units three times weekly induces normalization of alanine aminotransferase (ALT) activity and seroconversion of patients in about 40% of cases with B-virus-induced hepatitis at the end of treatment. The aim of this prospective open multicentre study is to give further data about the dosage and the long-term administration of α-interferon. Eight liver units in universities and hospitals have been involved in this trial. Twenty-one patients with chronic B hepatitis were selected for study.
Therapy protocol: The patients with chronic B hepatitis were treated with interferon-α2b (Intron A) for one year. If the patients had no response after three months, the dose was increased. After one year of therapy, the patients were observed for another six months.
Efficacy of the therapy: Sustained complete remission occurred in ten cases (47.6%); partial remission in five; four patients had no response; in one case, the disease had progressed; and one patient dropped out. Side-effects, apart from a flu-like syndrome, occurred in only a very few cases.
Conclusion: Long-term therapy with interferon-α2b for one year produced sustained complete remission in about half of the patients. In non-responders after three months’ therapy, increasing the dose of interferon had a beneficial effect. On the basis of these data, long-term therapy and higher dosage in non-responders can be recommended.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonino F. The Role of Interferon in Chronic Viral Hepatitis. F. Hoffmann-La Roche Ltd; 1992.
Lengyel G, Fehér J. Interferon kezelés virus okorta krónikus aktív hepatitisben. Ory Hetil. 1995;136:37.
Morgersen SC, Virilizer JL. Interferons. In: Gressor I, ed. Interferon. London: Academic Press; 1987:55.
Pár A. Krónikus vírushepatitisek: pathogenesis, prevencío, prognózis. Orv Hetil. 1992;133(Suppl. 1):137–40.
Samuel CE. The interferons. In: Pfeffer LM, ed. Mechanism of Interferon Action. Florida: CMC Press; 1987:111.
Chen G, Karayiannis P, McGarvay MJ et al. Subclasses of anti-HBe in chronic HBV infection: changes during treatment with interferon and predictors of response. Gut. 1989;30(Part 8):1123–8.
Samuel CE. Molecular mechanism of interferon action: ribosome associated protein P1 and protein synthesis initiation factor elF-2. Texas Rep Biol Med. 1982;41:463–70.
Sréter L, Fehér J. Az interferon klinikai alkalmazasa. Orv Hetil. 1991;132:507–12.
Isaacs A, Lindermann L. Virus interference. 1. The interferons. Proc R Soc London (Biology). 1975;147:258–67.
Fattovich G, Farci P, Rugge M et al. A randomized controlled trial of lymphoblastoid interferon-a in patients with chronic hepatitis B lacking HBeAg. Hepatology. 1992;15:584–9.
Revel M, Chabath J. Interferon activated genes. Trends Biochem Science. 1986;11:166–70.
Saksela E. In: Gressor I, ed. Interferon 3. London: Academic Press; 1981:45.
Hoofnagle JH, Peters M, Mullen KD et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology. 1988;95:1218–325.
Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A non-B hepatitis with recombinant human α-interferon: a preliminary report. N Engl J Med. 1986;315:1575–8.
Barbera C, Bortolotti F, Crivellaro C et al. Recombinant interferon-α2b hastens the rate of HBe-Ag clearance in children with chronic hepatitis B. Hepatology. 1994;20:287–90.
Ibrányi E, Nagy E, Szalay F et al. Krónikus aktiv B hepatitis interferon (Egiferon) kezelése. Orv Hetil. 1993;134:2645–7.
Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon-α2b regimens for the longterm treatment of chronic non-A non-B hepatitis. N Engl J Med. 1995;322:1457–62.
Reichard O, Glaumann H, Hrydén A et al. Two-year biochemical, virological and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon-α2b treatment. Hepatology. 1995;21:918–22.
Fehér J, Lengyel G, Dalmi L et al. Interferon-α2b kezelé chronicus C hepatitisben. Orv Hetil. 1996;137:1179–85.
Jacyna MR, Thomas HC. Antiviral therapy: hepatitis B. Br J Med Bull. 1990;446:368–82.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Lengyel, G. et al. (1997). Long-Term Interferon-α2b Therapy in Chronic Hepatitis B. A Prospective Multicentre Study in Hungary. In: Mózsik, G., Nagy, L., Pár, A., Rainsford, K.D. (eds) Cell Injury and Protection in the Gastrointestinal Tract. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5392-8_30
Download citation
DOI: https://doi.org/10.1007/978-94-011-5392-8_30
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6268-8
Online ISBN: 978-94-011-5392-8
eBook Packages: Springer Book Archive